APPENDICURE

First, though, I want to share some genuinely exciting science.

Recent research in colorectal cancer uncovered something surprising: bacteria living inside tumors may help the immune system attack cancer cells.

While the study was conducted in colorectal cancer, the findings raise important questions for appendix cancer research. Appendix tumors develop in the same gut environment as colorectal cancers, where bacteria and immune cells constantly interact – and the same bacterial species studied in this research have also been detected in appendiceal tumors.

Let’s break down what the researchers found and why it matters.

The Immune System Already Tries to Fight Cancer

Our immune system constantly patrols the body looking for infections and abnormal cells. One type of immune cell involved in this process is called a neutrophil.

Neutrophils are best known for fighting bacteria and infections. But researchers are increasingly learning that they also interact with tumors.

Inside tumors, neutrophils can behave in two very different ways:

• Sometimes helping tumors grow
• Sometimes attacking and destroying cancer cells

Scientists have been trying to understand what determines which role neutrophils play.

The Surprising Role of Bacteria Inside Tumors

Tumors in the digestive system often contain bacteria that originate from the gut microbiome.

One bacterium studied in this research is called Fusobacterium nucleatum, which is commonly found in colorectal tumors and has also been detected in appendiceal tumors.

Researchers discovered that when this bacterium is present inside tumors, it can trigger neutrophils to become cancer-fighting cells.

Here is how the process works:

1. Bacteria inside the tumor attract neutrophils.
2. The neutrophils detect the bacteria.
3. The bacteria activate the neutrophils through a receptor called Siglec-14.
4. Activated neutrophils release a mixture of antimicrobial enzymes and toxic molecules, including proteins such as elastase and myeloperoxidase, that can damage cancer cells.

In laboratory experiments, these activated neutrophils were able to kill colorectal cancer cells and suppress tumor growth in experimental models.

A different common gut bacterium, Bacteroides fragilis, did not trigger the same immune response.

In simple terms, certain bacteria may act like a signal that wakes up the immune system inside the tumor.

These findings come from recent peer-reviewed research investigating how Fusobacterium nucleatum interacts with neutrophils through the Siglec-14 immune receptor in colorectal tumors. Here is the original study: A Sweet Side to Fusobacterium

Genetics Also Plays a Role

The study also found that a person’s genetics may influence whether this immune response works.

Neutrophils rely on the Siglec-14 receptor to detect signals from Fusobacterium nucleatum.

When neutrophils carry this receptor, they can activate and release cancer-killing molecules. But some people carry a genetic variant that removes this receptor entirely. When that happens, neutrophils may still enter the tumor but do not activate their cancer-fighting program as effectively.

Interestingly, the Siglec-14 deletion variant appears at very different rates across populations:

• Fewer than 10% of people of European descent
• Up to 70% of people of East Asian descent

This difference has led some researchers to speculate that patient genetics. not just tumor biology, could help explain why studies of neutrophils in colorectal cancer sometimes show opposite survival patterns across populations.

Patients whose tumors contained Fusobacterium nucleatum, active neutrophils, and an intact Siglec-14 receptor tended to have the best outcomes in colorectal cancer.

Why This Matters for Appendix Cancer

Appendix cancers develop in the same microbial environment as the colon, which means bacteria may also influence these tumors.

Several studies examining appendiceal tumors and pseudomyxoma peritonei deposits have found bacteria present inside tumor tissue and mucin, including species such as:

• Fusobacterium
• Bacteroides
• Other gut microbes

Researchers are still trying to understand whether these bacteria promote tumor growth, influence immune responses, or affect how mucin tumors behave.

But the presence of bacteria inside appendiceal tumors suggests that the tumor microbiome could play a role in the disease.

Much of what scientists understand about appendix cancer today comes from discoveries first made in colorectal cancer research, which makes findings like these particularly interesting for rare cancer researchers.

The Mucin Mystery

Appendix cancers such as pseudomyxoma peritonei (PMP) produce large amounts of mucin — the thick, gel-like substance that can fill the abdomen.

Researchers know that tumor mutations help drive mucin production, particularly mutations in genes such as KRAS and GNAS. But those mutations alone do not fully explain why mucin production becomes so extreme.

Some scientists have proposed a hypothesis sometimes described as a mucin–microbe cycle:

1. Tumor cells produce mucin.
2. Mucin creates a protective environment where bacteria can survive.
3. Bacteria trigger inflammatory signaling pathways.
4. Those signals stimulate tumor cells to produce even more mucin.

Researchers are still studying whether this cycle occurs in appendix cancer, but it represents a compelling area of investigation.

Why the Tumor Microbiome Is Getting Attention

Cancer researchers increasingly view tumors as ecosystems, not just clusters of cancer cells.

Inside tumors there may be cancer cells, immune cells, blood vessels, connective tissue, and bacteria and other microbes – all interacting with each other.

Understanding this ecosystem may help explain why some tumors grow faster, why some patients respond better to treatment, and how the immune system interacts with cancer.

A Clue from Immunotherapy Research

Interest in the tumor microbiome has grown even more because studies in several cancers have shown that gut bacteria can influence how well patients respond to immunotherapy.

In melanoma, lung cancer, and other cancers, certain bacterial species appear to improve responses to immune checkpoint inhibitors.

This raises an important question: Could bacteria inside gastrointestinal tumors – including appendix cancer – influence how the immune system responds to treatment? Researchers are actively exploring that possibility.

Questions Worth Raising With Your Care Team

If you are being treated at a major cancer center, these findings may be worth discussing with your oncologist:

• Is the tumor microbiome being studied in appendix cancer?
• Are there clinical trials investigating microbiome–immune interactions in gastrointestinal cancers?
• Could immune cell patterns, such as neutrophil density, provide useful research insights?

These questions are still largely in the research domain, but awareness of this area is growing rapidly. Share this blog post with your care team.

What This Means for Patients

This research does not change current treatments for appendix cancer.

However, it highlights a rapidly growing area of science. Researchers are exploring whether the tumor microbiome could eventually help guide new strategies, such as modifying the tumor microbiome, activating immune cells inside tumors, or reducing signals that drive mucin production.

These ideas are still early in development. But they reflect an important shift in how scientists think about cancer. Tumors are not just clusters of cancer cells. They are complex ecosystems.

A Personal Note from Appendicure

Audrey Hepburn devoted the final years of her life to UNICEF, traveling to some of the world’s most vulnerable communities. Her last mission took her to Somalia in September 1992, where she witnessed a famine she described as “apocalyptic.” She called it the worst suffering she had ever seen.

Upon returning to Switzerland, she developed abdominal pain. A laparoscopy at Cedars-Sinai Medical Center in November 1992 revealed pseudomyxoma peritonei – a form of appendix cancer that had been growing slowly for years. She died at her home in Switzerland on January 20, 1993. She was 63.

Today, PMP is treatable. The cytoreductive surgery and HIPEC procedure now considered the standard of care for PMP did not exist in 1993. Audrey Hepburn’s disease is no longer a death sentence, but only if patients find their way to the right specialists, and only if research funding continues to advance treatment.

A biographical film about her life is now in development. If handled thoughtfully, this film could introduce millions of people to a disease that most have never heard of – the same disease affecting thousands of patients and families today.

Appendicure would love to work with the filmmakers to ensure that Audrey’s legacy of compassion also helps raise awareness for appendix cancer patients around the world.

Potential collaborations could include educational partnerships tied to the film’s release, awareness campaigns during the publicity cycle, and patient storytelling connected to Audrey’s humanitarian legacy.

If you know anyone connected to the film industry – producers, agents, studio executives, or anyone with ties to Imagine Entertainment or related projects – we would be grateful for an introduction.

Even a single connection could help turn this cultural moment into meaningful awareness and research support for appendix cancer patients.

You can reach us at: info@appendicure.com

The Bottom Line

Appendix cancer tumors may not exist in isolation. They may be shaped by a complex ecosystem that includes immune cells, bacteria, and the unique genetics of each patient.

Research like this suggests that microbes inside tumors could influence how the immune system responds to cancer — and understanding those relationships may eventually open new doors for treatment.

As scientists continue this work, Appendicure will keep bringing new research directly to patients and caregivers.

#appendixcancer #audreyhepburn #imagineentertainment #rarecancer #appendixcancerawareness